Resources

Publications

08/17/2023
- Oncology
Neratinib + Fulvestrant + Trastuzumab for HR-Positive, HER2-Negative, HER2-Mutant Metastatic Breast Cancer: Outcomes and Biomarker Analysis From the SUMMIT Trial
Annals of Oncology
08/17/2023
- Oncology
Prevalence of KRAS Subtype Alterations in Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases
IASLC WCLC 2023
08/17/2023
- Oncology
Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers
IASLC WCLC 2023
08/14/2023
- Oncology
NTRK Expression Is Common in Xanthogranuloma and Is Associated With the Solitary Variant
Journal of Cutaneous Pathology
07/28/2023
- Oncology
Overcoming the Challenges of Variant Calling In PMS2 High Homology Regions For Improved Lynch Syndrome Diagnosis Using Whole-Genome Sequencing
ISMB 2023
07/24/2023
- Oncology
Neurofibromatosis- and Schwannomatosis-Associated Tumors: Approaches to Genetic Testing and Counseling Considerations
American Journal of Medical Genetics
07/14/2023
- Oncology
Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency–Related Loss of Heterozygosity
Journal of the National Comprehensive Cancer Network
06/24/2023
- Clinical Trials
- Oncology
Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model
JCO Clinical Cancer Informatics
06/13/2023
- Oncology
A Deep-learning based RNA-seq Germline Variant Caller
Bioinformatics Advances
06/08/2023
- Oncology
Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor
Clinical Cancer Research

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61